SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

10x Genomics, Inc. – ‘10-Q’ for 6/30/22 – ‘R16’

On:  Monday, 8/8/22, at 7:30pm ET   ·   As of:  8/9/22   ·   For:  6/30/22   ·   Accession #:  1770787-22-49   ·   File #:  1-39035

Previous ‘10-Q’:  ‘10-Q’ on 5/5/22 for 3/31/22   ·   Next:  ‘10-Q’ on 11/3/22 for 9/30/22   ·   Latest:  ‘10-Q’ on 4/30/24 for 3/31/24   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/09/22  10x Genomics, Inc.                10-Q        6/30/22   56:5.4M

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.08M 
 2: EX-10.1     Material Contract                                   HTML    133K 
 3: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 4: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 5: EX-32.1     Certification -- §906 - SOA'02                      HTML     19K 
 6: EX-32.2     Certification -- §906 - SOA'02                      HTML     19K 
12: R1          Cover Page                                          HTML     74K 
13: R2          Condensed Consolidated Balance Sheets               HTML    128K 
14: R3          Condensed Consolidated Statements of Operations     HTML    102K 
15: R4          Condensed Consolidated Statements of Comprehensive  HTML     46K 
                Loss                                                             
16: R5          Condensed Consolidated Statements of Stockholders?  HTML     79K 
                Equity                                                           
17: R6          Condensed Consolidated Statements of Cash Flows     HTML    120K 
18: R7          Description of Business and Basis of Presentation   HTML     24K 
19: R8          Summary of Significant Accounting Policies          HTML     30K 
20: R9          Other Financial Statement Information               HTML    107K 
21: R10         Commitments and Contingencies                       HTML     38K 
22: R11         Capital Stock                                       HTML     24K 
23: R12         Equity Incentive Plans                              HTML     48K 
24: R13         Net Loss Per Share                                  HTML     34K 
25: R14         Subsequent Events                                   HTML     20K 
26: R15         Summary of Significant Accounting Policies          HTML     43K 
                (Policies)                                                       
27: R16         Other Financial Statement Information (Tables)      HTML    120K 
28: R17         Commitments and Contingencies (Tables)              HTML     33K 
29: R18         Equity Incentive Plans (Tables)                     HTML     50K 
30: R19         Net Loss Per Share (Tables)                         HTML     33K 
31: R20         Summary of Significant Accounting Policies -        HTML     19K 
                Additional Information (Detail)                                  
32: R21         Other Financial Statement Information -             HTML     47K 
                Available-for-Sale Securities (Details)                          
33: R22         Other Financial Statement Information - Additional  HTML     36K 
                Information (Detail)                                             
34: R23         Other Financial Statement Information -             HTML     36K 
                Contractual Maturities of Marketable Securities                  
                (Details)                                                        
35: R24         Other Financial Statement Information - Schedule    HTML     28K 
                of Inventory (Detail)                                            
36: R25         Other Financial Statement Information - Schedule    HTML     34K 
                of Accrued Compensation and Related Benefits                     
                (Detail)                                                         
37: R26         Other Financial Statement Information - Schedule    HTML     40K 
                of Accrued Expense And Other Current Liabilities                 
                (Detail)                                                         
38: R27         Other Financial Statement Information - Schedule    HTML     25K 
                of Changes in the Reserve for Product Warranties                 
                (Detail)                                                         
39: R28         Other Financial Statement Information - Revenue     HTML     22K 
                Recognition (Details)                                            
40: R29         Other Financial Statement Information - Schedule    HTML     30K 
                of Revenue by Source (Detail)                                    
41: R30         Other Financial Statement Information - Schedule    HTML     35K 
                of Revenue by Geographic Region (Details)                        
42: R31         Commitments and Contingencies - Additional          HTML     24K 
                Information (Detail)                                             
43: R32         Commitments and Contingencies - Summary of          HTML     40K 
                Company's Operating Lease Liabilities (Detail)                   
44: R33         Commitments and Contingencies - Summary of          HTML     22K 
                Additional Information Related to Operating Leases               
                (Detail)                                                         
45: R34         Capital Stock - Additional Information (Detail)     HTML     32K 
46: R35         Equity Incentive Plans - Additional Information     HTML     29K 
                (Detail)                                                         
47: R36         Equity Incentive Plans - Recorded Stock-Based       HTML     28K 
                Compensation Expense in the Condensed Consolidated               
                Statement of Operations (Details)                                
48: R37         Equity Incentive Plans - Summary of RSU Activity    HTML     41K 
                (Detail)                                                         
49: R38         Equity Incentive Plans - Summary of Company's       HTML     41K 
                Stock Option Activity (Details)                                  
50: R39         Net Loss Per Share - Shares of Common Stock         HTML     35K 
                Equivalents Were Excluded From The Computation of                
                Diluted Net Loss Per Share (Details)                             
51: R40         Subsequent Events (Details)                         HTML     26K 
54: XML         IDEA XML File -- Filing Summary                      XML     95K 
52: XML         XBRL Instance -- txg-20220630_htm                    XML   1.08M 
53: EXCEL       IDEA Workbook of Financial Reports                  XLSX     82K 
 8: EX-101.CAL  XBRL Calculations -- txg-20220630_cal                XML    179K 
 9: EX-101.DEF  XBRL Definitions -- txg-20220630_def                 XML    258K 
10: EX-101.LAB  XBRL Labels -- txg-20220630_lab                      XML   1.06M 
11: EX-101.PRE  XBRL Presentations -- txg-20220630_pre               XML    571K 
 7: EX-101.SCH  XBRL Schema -- txg-20220630                          XSD     99K 
55: JSON        XBRL Instance as JSON Data -- MetaLinks              291±   441K 
56: ZIP         XBRL Zipped Folder -- 0001770787-22-000049-xbrl      Zip    496K 


‘R16’   —   Other Financial Statement Information (Tables)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.22.2
Other Financial Statement Information (Tables)
6 Months Ended
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Marketable Securities
Available-for-sale securities at June 30, 2022 consisted of the following (in thousands):
Amortized CostGross Unrealized GainsGross Unrealized LossesFair Value Fair Value Measurement
Cash equivalents:
Money market funds$225,176 $— $— $225,176 Level 1
Marketable securities:
Corporate debt securities161,622 — (2,733)158,889 Level 2
Government debt securities51,746 (883)50,872 Level 2
Asset-backed securities15,907 — (122)15,785 Level 2
Total available-for-sale securities$454,451 $$(3,738)$450,722 
Debt Securities, Available-for-sale
The contractual maturities of marketable securities as of June 30, 2022 were as follows (in thousands):
Amortized CostFair Value
Due in one year or less$97,324 $95,930 
Due after one year to five years131,951 129,616 
Total marketable securities$229,275 $225,546 
Schedule of Inventory
Inventory was comprised of the following (in thousands):
June 30,
2022
December 31,
2021
Purchased materials$28,291 $31,954 
Work in progress21,846 14,052 
Finished goods20,509 13,960 
Inventory$70,646 $59,966 
Schedule of Accrued Compensation and Related Benefits
Accrued compensation and related benefits were comprised of the following as of the dates indicated (in thousands):
June 30,
2022
December 31,
2021
Accrued payroll and related costs$3,450 $3,978 
Employee stock purchase program liability754 1,693 
Accrued bonus11,294 16,558 
Accrued commissions4,055 3,417 
Accrued acquisition-related compensation2,156 4,430 
Accrued vacation1,403 1,172 
Other393 378 
Accrued compensation and related benefits$23,505 $31,626 
Schedule of Accrued Expense and Other Current Liabilities
Accrued expenses and other current liabilities were comprised of the following as of the dates indicated (in thousands):
June 30,
2022
December 31,
2021
Accrued legal and related costs$2,313 $2,425 
Accrued license fee6,008 6,214 
Accrued royalties for licensed technologies4,166 4,415 
Accrued property and equipment25,833 15,361 
Accrued professional services4,332 8,593 
Product warranties1,430 994 
Customer deposits888 954 
Taxes payable1,445 4,622 
Accrued lab supplies1,884 2,056 
Other4,923 5,275 
Accrued expenses and other current liabilities$53,222 $50,909 
Schedule of Changes in the Reserve for Product Warranties
Changes in the reserve for product warranties were as follows for the periods indicated (in thousands):
Six Months Ended
June 30,
20222021
Beginning of period$994 $399 
Amounts charged to cost of revenue1,983 1,242 
Repairs and replacements(1,547)(1,064)
End of period$1,430 $577 
Schedule of Revenue by Source
The following table represents revenue by source for the periods indicated (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
Instruments$14,736 $16,877 $29,165 $28,002 
Consumables97,934 97,146 195,884 190,225 
Services1,939 1,819 4,056 3,436 
Total revenue$114,609 $115,842 $229,105 $221,663 
Schedule of Revenue by Geographic Location
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
June 30,
Six Months Ended
June 30,
2022202120222021
United States$69,373 $64,001 $126,814 $114,307 
Europe, Middle East and Africa25,608 28,772 46,140 47,942 
China9,087 12,874 29,847 36,514 
Asia-Pacific (excluding China)9,026 8,431 22,543 19,635 
North America (excluding United States)1,515 1,764 3,761 3,265 
Total revenue$114,609 $115,842 $229,105 $221,663 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-Q’ Filing    Date    Other Filings
Filed as of:8/9/22
Filed on:8/8/228-K
For Period end:6/30/22
12/31/2110-K
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/15/24  10x Genomics, Inc.                10-K       12/31/23   95:15M
 2/16/23  10x Genomics, Inc.                10-K       12/31/22   93:23M


3 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/26/20  10x Genomics, Inc.                8-K:5,9     3/26/20    2:130K                                   Donnelley … Solutions/FA
 9/16/19  10x Genomics, Inc.                8-K:3,5,7,8 9/13/19    4:207K                                   Donnelley … Solutions/FA
 8/19/19  10x Genomics, Inc.                S-1                   24:13M                                    Donnelley … Solutions/FA
Top
Filing Submission 0001770787-22-000049   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Wed., May 15, 9:37:37.2am ET